RESUMEN
OBJECTIVE: To provide updates on the epidemiology and recommendations for management of candidemia in patients with critical illness. DATA SOURCES: A literature search using the PubMed database (inception to March 2023) was conducted using the search terms "invasive candidiasis," "candidemia," "critically ill," "azoles," "echinocandin," "antifungal agents," "rapid diagnostics," "antifungal susceptibility testing," "therapeutic drug monitoring," "antifungal dosing," "persistent candidemia," and "Candida biofilm." STUDY SELECTION/DATA EXTRACTION: Clinical data were limited to those published in the English language. Ongoing trials were identified through ClinicalTrials.gov. DATA SYNTHESIS: A total of 109 articles were reviewed including 25 pharmacokinetic/pharmacodynamic studies and 30 studies including patient data, 13 of which were randomized controlled clinical trials. The remaining 54 articles included fungal surveillance data, in vitro studies, review articles, and survey data. The current 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Management of Candidiasis provides recommendations for selecting empiric and definitive antifungal therapies for candidemia, but data are limited regarding optimized dosing strategies in critically ill patients with dynamic pharmacokinetic changes or persistent candidemia complicated. RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: Outcomes due to candidemia remain poor despite improved diagnostic platforms, antifungal susceptibility testing, and antifungal therapy selection for candidemia in critically ill patients. Earlier detection and identification of the species causing candidemia combined with recognition of patient-specific factors leading to dosing discrepancies are crucial to improving outcomes in critically ill patients with candidemia. CONCLUSIONS: Treatment of candidemia in critically ill patients must account for the incidence of non-albicans Candida species and trends in antifungal resistance as well as overcome the complex pathophysiologic changes to avoid suboptimal antifungal exposure.
Asunto(s)
Candidemia , Adulto , Humanos , Candidemia/diagnóstico , Candidemia/tratamiento farmacológico , Candidemia/epidemiología , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Enfermedad Crítica , Equinocandinas/farmacología , Equinocandinas/uso terapéutico , Candida , Unidades de Cuidados Intensivos , Pruebas de Sensibilidad MicrobianaRESUMEN
BACKGROUND: We investigated the neutralization performance of various automated blood culture systems for antifungal agents with regard to the most commonly isolated Candida species. METHODS: In this study, we evaluated the time to detection (TTD) of simulated candidemia for 6 Candida spp. (C. albicans, C. auris, C. glabrata, C. krusei, C. parapsilosis, and C. tropicalis) in 3 automated blood culture systems (BACTEC™ FX, BACT/ALERT® 3D, and BACT/ALERT® VIRTUO®), with or without trough and peak levels of eight antifungal agents (amphotericin B, anidulafungin, caspofungin, fluconazole, itraconazole, micafungin, posaconazole, and voriconazole). RESULTS: Caspofungin and micafungin significantly prolonged the TTDs for most of the tested strains in the 3 blood culture instruments, especially at peak concentrations. CONCLUSION: Peak concentrations of caspofungin and micafungin influence the performance of blood culture detection systems. Therefore, one should be careful about the possibility of prolonged TTDs for candidemia when using the abovementioned antifungal agents.
Asunto(s)
Candidemia , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Candida , Candida albicans , Candida glabrata , Candida parapsilosis , Candida tropicalis , Candidemia/diagnóstico , Candidemia/tratamiento farmacológico , Candidemia/prevención & control , Caspofungina , Fluconazol , Humanos , Micafungina , Pruebas de Sensibilidad MicrobianaRESUMEN
RATIONALE: Candida bloodstream infection continues to be a significant cause of mortality in premature infants. Amphotericin B has been recommended as the primary treatment; however, its use is limited due to drug-induced nephrotoxicity and amphotericin B-resistant candidemia. PATIENT CONCERNS: The gestational age was 29 (+6) weeks, and birth weight was 1760âg. DIAGNOSIS: The infant was diagnosed with Candida parapsilosis bloodstream infection. INTERVENTIONS: Fluconazole, 12âmg/kg/day, combined with caspofungin (loading dose 3âmg/kg, at a maintenance dose of 2âmg/kg every 24âh) therapy was administered to premature infant with Candida bloodstream infection. When fluconazole or caspofungin was used to treat Candida bloodstream infection in preterm infants, the blood cultures of the infant remained positive for Candida parapsilosis. OUTCOMES: All persistent candidemia resolved on fluconazole combined with caspofungin therapy. There were no adverse effects, hepatotoxicity, nephrotoxicity, anemia, or thrombocytopenia. LESSONS: Fluconazole combined with caspofungin successfully treated Candida bloodstream infection in premature infants at 29â+â6 weeks' gestational age, but large-scale clinical trials are required.
Asunto(s)
Antifúngicos/uso terapéutico , Candida parapsilosis/aislamiento & purificación , Candidemia/tratamiento farmacológico , Caspofungina/uso terapéutico , Fluconazol/uso terapéutico , Anfotericina B/uso terapéutico , Candida parapsilosis/efectos de los fármacos , Candidemia/diagnóstico , Femenino , Humanos , Recién Nacido , Recien Nacido Prematuro , Masculino , Pruebas de Sensibilidad Microbiana , Resultado del TratamientoRESUMEN
BACKGROUND: Fast diagnostic tests providing earlier identification (ID) of pathogens, and antimicrobial susceptibility testing (AST) may reduce time to appropriate antimicrobial therapy (AAT), decrease mortality, and facilitate antimicrobial deescalation (ADE). Our objective was to determine the theoretical reduction in time to AAT and opportunities for ADE with Accelerate PhenoTM System (AXDX). METHODS: The prospective cohort (April 14, 2016 through June 1, 2017) was from the Barnes-Jewish Hospital, a 1250-bed academic center. Emergency department (ED) or intensive care unit (ICU) blood cultures Gram-stain positive for gram-negative bacilli (GNB) or yeast. AXDX was used in parallel with standard-of-care (SOC) diagnostics to determine differences in time to pathogen ID and AST. Theoretical opportunities for ADE from AXDX results were determined. RESULTS: In total, 429 blood cultures were screened, 153 meeting inclusion criteria: 110 on-panel GNB, 10 Candida glabrata, and 5 Candida albicans. For GNB SOC, median time from blood culture positivity to ID and AST were 28.2 and 52.1 h. Median time to ID and AST after AXDX initiation was 1.37 and 6.7 h for on-panel organisms. For on-panel Candida, time to ID was approximately 21 h faster with AXDX. ADE or AAT was theoretically possible with AXDX in 48.4%. Of on-panel organisms, 24.0% did not receive initial AAT. In-hospital mortality was 46.7% without initial AAT, and 11.6% with AAT. Coverage of AXDX was 75.3%, specificity 99.7%, positive predictive value (PPV) 96.0%, and negative predictive value (NPV) 97.6%. On-panel sensitivity was 91.5%, specificity 99.6%, PPV 96.0%, and NPV 99.0%. CONCLUSIONS: AXDX provides more rapid ID and AST for GNB and ID for yeast than SOC. AXDX could potentially reduce time to AAT and facilitate ADE.
Asunto(s)
Antiinfecciosos/uso terapéutico , Bacteriemia/diagnóstico , Cultivo de Sangre/instrumentación , Candidemia/diagnóstico , Infecciones por Bacterias Gramnegativas/diagnóstico , Juego de Reactivos para Diagnóstico , Anciano , Bacteriemia/tratamiento farmacológico , Bacteriemia/microbiología , Cultivo de Sangre/normas , Candida/aislamiento & purificación , Candidemia/tratamiento farmacológico , Candidemia/microbiología , Femenino , Bacterias Gramnegativas/aislamiento & purificación , Infecciones por Bacterias Gramnegativas/sangre , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Infecciones por Bacterias Gramnegativas/microbiología , Humanos , Masculino , Pruebas de Sensibilidad Microbiana/instrumentación , Pruebas de Sensibilidad Microbiana/normas , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Estudios Prospectivos , Sensibilidad y Especificidad , Nivel de Atención , Factores de Tiempo , Tiempo de TratamientoRESUMEN
OBJECTIVES: This study investigated the feasibility of using whole-genome sequencing (WGS) for the prediction of antifungal resistance in anidulafungin-resistant Candida tropicalis candidaemia isolates. METHODS: Next-generation sequencing was performed for three anidulafungin-resistant C. tropicalis isolates on an Illumina MiSeq system with in-house bioinformatics analysis. RESULTS: Mutations in Fks1p associated with anidulafungin resistance were identified. Other mutations associated with varying levels of phenotypic resistance to fluconazole were also identified. CONCLUSIONS: These data demonstrate the potential to predict antifungal resistance using WGS. With improving technology, real-time WGS may be used for tailoring effective antifungal therapy in patients with candidaemia.
Asunto(s)
Anidulafungina/farmacología , Antifúngicos/farmacología , Candida tropicalis/efectos de los fármacos , Candida tropicalis/genética , Farmacorresistencia Fúngica/genética , Candidemia/diagnóstico , Candidemia/tratamiento farmacológico , Genoma Fúngico , Humanos , Pruebas de Sensibilidad Microbiana , Mutación , Secuenciación Completa del GenomaRESUMEN
Many uncommon Candida spp. (species other than C. albicans, C. parapsilosis, C. glabrata, C. tropicalis, and C. krusei) have been shown to emerge in tertiary care facilities. We aimed to investigate these uncommon candidemia in children. Forty-six cases of candidemia caused by uncommon Candida spp. were identified during 2003-2015 from a medical center in Taiwan. The most common specie was C. guilliermondii (31.2%), followed by C. lusitaniae (18.8%) and C. metapsilosis (18.8%). These cases were analyzed and compared with 148 episodes of C. albicans candidemia. The incidence density of uncommon Candida spp. candidemia and the proportion to all candidemia episodes increased substantively during the study period. Prior exposure to azoles was uncommon in the 30 days prior to infection, but fluconazole resistant strains were significantly more common (n = 19, 41.3%). The increased incidence density of uncommon Candida spp. candidemia was associated with increasing use of antifungal agents. No differences in demographics, underlying comorbidities, risk factors, clinical features, dissemination, and 30-day mortality were found between uncommon Candida spp. and C. albicans candidemia. Patients with uncommon Candida spp. candidemia were more likely to require modifications in antifungal treatment and receive echinocandin drugs (43.5% vs 21.6%, p = 0.007). Candidemia caused by uncommon Candida spp. had poorer response to antifungal treatment, led to longer duration of candidemia (median 4.0 versus 2.5 days, p = 0.008), and had a higher treatment failure rate (56.5% vs 38.5%, p = 0.040).
Asunto(s)
Antifúngicos/uso terapéutico , Candida/clasificación , Candidemia/tratamiento farmacológico , Candidemia/epidemiología , Candidemia/microbiología , Adolescente , Antifúngicos/clasificación , Candida/aislamiento & purificación , Candidemia/diagnóstico , Niño , Preescolar , Enfermedades Transmisibles Emergentes/diagnóstico , Enfermedades Transmisibles Emergentes/tratamiento farmacológico , Enfermedades Transmisibles Emergentes/epidemiología , Enfermedades Transmisibles Emergentes/microbiología , Femenino , Humanos , Incidencia , Lactante , Recién Nacido , Masculino , Pruebas de Sensibilidad Microbiana , Mortalidad , Pronóstico , Estudios Retrospectivos , Factores de Riesgo , Taiwán/epidemiología , Resultado del TratamientoRESUMEN
Candidemia is the main invasive fungal disease among hospitalized patients. Several breakthrough candidemia (BrC) cases have been reported, but few studies evaluate the epidemiology, risk factors, molecular characterization, antifungal susceptibility profile and outcome of those patients, especially in developing countries and including patients using broad spectrum antifungals. We conducted a retrospective study from 2011 to 2016, including patients aged 12 years or older with candidemia. Epidemiological characteristics and risk factors for candidemia were evaluated and compared with patients with BrC using univariate and multivariate analysis. Sequential Candida isolates from BrC were identified by internal transcribed spacer sequencing, genotyped with amplified fragment length polymorphism fingerprinting (AFLP), and tested for antifungal susceptibility. From 148 candidemia episodes, 27 breakthrough episodes (18%) were identified, with neutropenia and mucositis being independent risk factors for BrC. Candida non-albicans was more frequent in the BrC group (P < .001). AFLP showed high correlation with conventional methods of identification among breakthrough isolates and a high genetic similarity among isolates from the same patient was observed. C. albicans was the most susceptible species with low MIC values for all antifungal agents tested. In contrast, we found isolates of C. glabrata, C. parapsilosis and C. tropicalis resistant to triazoles and echinocandins. In conclusion, BrC occurred mainly in severely immunosuppressed patients, with neutropenia and mucositis. Mortality did not differ between the groups. Candida non-albicans species were more recovered from BrC, with C. albicans being the most susceptible to antifungals.
Asunto(s)
Profilaxis Antibiótica , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Candida/efectos de los fármacos , Candidemia/tratamiento farmacológico , Enfermedad Aguda , Adolescente , Adulto , Análisis del Polimorfismo de Longitud de Fragmentos Amplificados , Brasil , Candida/clasificación , Candida/aislamiento & purificación , Candidemia/diagnóstico , Candidemia/epidemiología , Candidemia/microbiología , Niño , Farmacorresistencia Fúngica/efectos de los fármacos , Femenino , Humanos , Infecciones Fúngicas Invasoras/tratamiento farmacológico , Infecciones Fúngicas Invasoras/prevención & control , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Profilaxis Pre-Exposición , Estudios Retrospectivos , Factores de Riesgo , Resultado del Tratamiento , Adulto JovenRESUMEN
Candida species frequently cause blood stream infections and are reported to be the third to tenth most commonly isolated pathogens. Guidelines and standardised treatment algorithms provided by professional organisations aim to facilitate decision-making regarding diagnosis, management and treatment of candidaemia. In routine clinical practise, however, it may be challenging to comply with these guidelines. The reasons include lack of familiarity or feasibility to adherence, but also their length and complexity. There is no tool to measure guideline adherence currently. To provide such a tool, we reviewed the current guidelines provided by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) and by the Infectious Diseases Society of America (IDSA), and selected the strongest recommendations for management quality as the bases for our scoring tool. Factors incorporated were diagnostic (blood cultures, echocardiography, ophthalmoscopy, species identification) and follow-up procedures (repeat blood cultures until negative result) as well as key treatment parameters (echinocandin treatment, step down to fluconazole depending on susceptibility result, CVC removal). The EQUAL Candida Score weighs and aggregates factors recommended for the ideal management of candidaemia and provides a tool for antifungal stewardship as well as for measuring guideline adherence.
Asunto(s)
Antifúngicos/uso terapéutico , Candidemia/tratamiento farmacológico , Candidemia/microbiología , Adhesión a Directriz/organización & administración , Programas de Optimización del Uso de los Antimicrobianos , Candida/efectos de los fármacos , Candida/aislamiento & purificación , Candidemia/diagnóstico , Candidiasis/tratamiento farmacológico , Manejo de la Enfermedad , Equinocandinas/uso terapéutico , Fluconazol/uso terapéutico , Humanos , Pruebas de Sensibilidad Microbiana , Guías de Práctica Clínica como AsuntoRESUMEN
Studies have demonstrated that the combination of antimicrobial stewardship programs (ASP) and rapid organism identification improves outcomes in bloodstream infections (BSI) but have not controlled for the incremental contribution of the individual components. Hospitalized adult patients with blood culture pathogens on a rapid, multiplex PCR-based blood culture identification panel (BCID) that included 19 bacterial species, 5 Candida spp., and 4 antimicrobial resistance genes were studied over sequential time periods in a pre-post quasiexperimental study in 3 groups in the following categories: conventional organism identification (controls), conventional organism identification with ASP (AS), and BCID with ASP (BCID). Clinical and economic outcomes were compared between groups. There were 783 patients with positive blood cultures; of those patients, 364 (115 control, 104 AS, and 145 BCID) met inclusion criteria. The time from blood culture collection to organism identification was shorter in the BCID group (17 h; P < 0.001) than in the control group (57 h) or the AS group (54 h). The BCID group had a shorter time to effective therapy (5 h; P < 0.001) than the control group (15 h) or AS group (13 h). The AS (57%) and BCID (52%) groups had higher rates of antimicrobial de-escalation than the control group (34%), with de-escalation occurring sooner in the BCID group (48 h; P = 0.034) than in the AS group (61 h) or the control group (63 h). No difference between the control group, AS group, and BCID group was seen with respect to mortality, 30-day readmission, intensive care unit length of stay (LOS), postculture LOS, or costs. In patients with BSI, ASP alone improved antimicrobial utilization. Addition of BCID to an established ASP shortened the time to effective therapy and further improved antimicrobial use compared to ASP alone, even in a setting of low antimicrobial resistance rates.
Asunto(s)
Antibacterianos/uso terapéutico , Bacteriemia/diagnóstico , Cultivo de Sangre/métodos , Candidemia/diagnóstico , Utilización de Medicamentos/normas , Pruebas de Sensibilidad Microbiana/métodos , Reacción en Cadena de la Polimerasa/métodos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Bacteriemia/tratamiento farmacológico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Ensayos Clínicos Controlados no Aleatorios como Asunto , Factores de Tiempo , Resultado del Tratamiento , Adulto JovenRESUMEN
Candidemia and invasive candidiasis are major causes of morbidity and mortality, and their incidence is increasing because of the growing complexity of patients. Five species of Candida (Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis and Candida krusei) account for more than 90% of all diagnosed cases, but their relative frequency varies depending on the population involved, geographical region, previous anti-fungal exposure, and patient age. The best evidence regarding the anti-fungal treatment for invasive candidiasis comes from randomized controlled trials in which more than 85% of the recruited patients had candidemia. In the case of less frequent forms of invasive candidiasis, the recommendations are based on retrospective studies, meta-analyses (when available) and experts' opinions. A pre-emptive approach based on biomarkers and clinical rules is recommended because of the high rate of infection-related mortality among critically ill patients.
Asunto(s)
Antifúngicos/uso terapéutico , Candidemia/tratamiento farmacológico , Candidiasis Invasiva/tratamiento farmacológico , Equinocandinas/uso terapéutico , Candida/clasificación , Candidemia/diagnóstico , Candidiasis Invasiva/diagnóstico , Farmacorresistencia Fúngica , Diagnóstico Precoz , Humanos , Pruebas de Sensibilidad Microbiana , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
UNLABELLED: aim: To study the factors influencing the results of treatment for candidemia (CE) in patients with blood system tumors. SUBJECTS AND METHODS: The investigation enrolled patients with hemoblastoses and CE. 30-day all-cause mortality was analyzed. RESULTS: In an 8-year period (2006-2013), CE was diagnosed in 55 patients (median age, 50 years); there was a preponderance of patients with lymphomas (47%) and acute leukemias (27%). The causative agents of CE were C. albicans (38%), C. parapsilosis (17%), C. krusei (11%), C. guilliermondii (11%), C. lusitaniae (6%), C. tropicalis (6%), C. glabrata (3%), C. famata (3%), C. pelliculosa (3%), and C. kefyr (2%). 30-day all-cause mortality was 43.6%. Recovery was statistically significantly more frequently seen following removal of a central venous catheter (67% versus 13%; p=0.004; odds ratio (OR), 14); after use of an antifungal drug on day 1 of isolation of Candida spp. from blood cultures (62% versus 13%; p=0.01; OR, 12); and that of echocandin as a first-line agent (86% versus 42%; p=0.005; OR, 8.4). The poor predictors were septic shock (5% recovery rate versus 86% in the patients without this factor; p<0.0001; OR, 0.01), granulocytopenia (42% versus 88%; p=0.001; OR, 0.1); use of amphotericin B as a first-line drug (26% versus 71%; p=0.002; OR, 0.15); hemoblastosis recurrence or resistance (39% versus 73%; p=0.01; OR, 0.24). Multivariate analysis showed the positive impact of antifungal administration on day 1 of isolation of Candida spp. from blood cultures on treatment results (p=0.03; OR, 27). CONCLUSION: High mortality rates were noted in the patients with hemoblastoses and CE. The recovery rates were statistically significantly higher after use of echinocandin as a first-line agent, after that of an antifungal agent on day 1 of positive blood cultures, after removal of a central venous catheter, and hemoblastosis remission.
Asunto(s)
Antifúngicos/uso terapéutico , Candida/aislamiento & purificación , Candidemia/tratamiento farmacológico , Neoplasias Hematológicas/complicaciones , Adolescente , Adulto , Anciano , Candidemia/complicaciones , Candidemia/diagnóstico , Femenino , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: Candida parapsilosis was the most common species causing candidemia in the 2010 China Hospital Invasive Fungal Surveillance Net (CHIF-NET) database. Compared to Candida albicans, the description of azole resistance and mechanisms in C. parapsilosis is very limited. We report a patient with C. parapsilosis candidemia over several months, due to a probable intravascular source, who developed fluconazole resistance after prolonged treatment. CASE PRESENTATION: An 82 year-old male had a hospital admission of approximately 1.5 years duration. He was initially admitted with acute pancreatitis. Prior to succumbing to the illness, he developed candidemia and treated with three antifungal drugs for nearly 5 months, at suboptimal doses and without source control. Following treatment, 6 blood cultures were still positive for C. parapsilosis. The last 2 strains were resistant to fluconazole (MICs 32 µg/mL) and intermediate to voriconazole (MICs 0.5 µg/mL). Microsatellite multilocus analysis indicated that the 6 isolates from the patient belonged to a single genotype. The first 4 isolates were susceptible to fluconazole (MICs 2 µg/mL) and voriconazole (MICs 0.015-0.03 µg/mL), which were slightly higher than susceptible control strains from other patients. Overexpression of MDR1 genes were detected in the two resistant isolates, and this was associated with a homozygous mutation in MRR1 genes (T2957C /T2957C), with the amino acid exchange L986P. CONCLUSIONS: This case corroborates that the resistant C. parapsilosis isolates can emerge in the setting of complicated infections and the extensive use of antifungal agents, emphasizing the need for standardizing and improving the antifungal treatment as well as source control in the treatment of infection diseases.
Asunto(s)
Antifúngicos/uso terapéutico , Candida/aislamiento & purificación , Candidemia/diagnóstico , Farmacorresistencia Fúngica , Fluconazol/uso terapéutico , Anciano de 80 o más Años , Antifúngicos/farmacología , Candida/efectos de los fármacos , Candida/genética , Candidemia/tratamiento farmacológico , Candidemia/microbiología , China , Farmacorresistencia Fúngica/genética , Fluconazol/farmacología , Humanos , Masculino , Pruebas de Sensibilidad MicrobianaRESUMEN
Antecedentes. La candidiasis es una de las micosis más importantes entre las frecuentes infecciones invasivas por hongos en pacientes hospitalizados; por esta razón, el tratamiento antifúngico es un desafío constante. Objetivos. Este estudio evaluó la sensibilidad in vitro de aislamientos clínicos de Candida albicans procedentes de hemocultivos a fluconazol, anfotericina B y anidulafungina, aislados en un hospital del sur de Brasil. Métodos. Para los estudios de sensibilidad in vitro se testaron 153 aislamientos de C. albicans frente a los fármacos mencionados, en concordancia con el Clinical and Laboratory Standards Institute. Se determinaron las concentraciones inhibitorias y fungicidas mínimas (CMI y CMF, respectivamente) de cada fármaco y el punto de corte epidemiológico (ECV). Resultados. Todas las cepas fueron susceptibles a anidulafungina, con la CMI y CMF <= 1 mg/ml; sin embargo, cuando se comparó con el ECV, un 3% de los aislamientos presentó valores más altos. Con relación al fluconazol, un 96% fue sensible, un 3%, susceptible dependiente de la dosis, y un 1%, resistente. Sin embargo, se observó que el 21% de los aislamientos presentó valores mayores que el ECV. Bajo la acción de la anfotericina B, una de las cepas fue resistente y, el resto, susceptible, de acuerdo con la CMF; por otro lado, un 1,5% de los aislamientos presentó valores mayores al ECV. Conclusiones. Los aislamientos de C. albicans presentaron mayor sensibilidad a la anidulafungina y un 90% de estas cepas (CMI90) presentó los menores valores frente a la anfotericina B. Basados en el ECV y la nueva clasificación descrita por Pfaller, los aislamientos podrían ser resistentes a fluconazol, lo que demuestra la importancia de la asociación y revisión de estos parámetros (AU)
Asunto(s)
Humanos , Masculino , Femenino , Candida albicans , Candida albicans/aislamiento & purificación , Candidemia/diagnóstico , Candidemia/microbiología , Anfotericina B/uso terapéutico , Pruebas de Sensibilidad Microbiana/métodos , Pruebas de Sensibilidad Microbiana/normas , Pruebas de Sensibilidad Microbiana , Sensibilidad y Especificidad , Fluconazol/uso terapéutico , Anticuerpos Antifúngicos/análisis , Antifúngicos/análisis , Antifúngicos/aislamiento & purificación , Antifúngicos/uso terapéuticoRESUMEN
BACKGROUND: Candida albicans is the predominant isolate in many neonatal fungal bloodstream infections (BSIs), so fluconazole is used as empiric antifungal therapy. AIM: To determine the predominant organisms, antifungal sensitivity patterns, clinical and demographic risk factors and crude mortality rate in neonatal fungal BSI cases. SUBJECTS AND METHODS: This is a review of all neonatal fungal BSI cases between January 2007 and December 2011. RESULTS: Fifty-nine patients were included in the study. Candida parapsilosis (54.2%) was isolated in majority of the cases, followed by C. albicans (27.1%). Fluconazole resistance was present in 16 of 32 cases of C. parapsilosis versus 1 of 16 cases of C. albicans (P = 0.003). Mortality rate was 45.8%. Surgical problems were present in 55.9%. Death was significantly associated with lower birth weight (P = 0.046) and necrotizing enterocolitis (P = 0.034). CONCLUSIONS: The increase in neonatal fungal BSI and resistant organisms highlights the need to review use of routine empiric fluconazole and to implement preventive measures.
Asunto(s)
Antifúngicos/uso terapéutico , Candida/aislamiento & purificación , Candidemia/diagnóstico , Candidiasis/diagnóstico , Antifúngicos/farmacología , Peso al Nacer , Candida/clasificación , Candida/efectos de los fármacos , Candidemia/tratamiento farmacológico , Candidemia/epidemiología , Candidemia/microbiología , Candidiasis/tratamiento farmacológico , Candidiasis/microbiología , Candidiasis/mortalidad , Farmacorresistencia Fúngica , Femenino , Fluconazol/farmacología , Fluconazol/uso terapéutico , Humanos , Incidencia , Recién Nacido , Masculino , Pruebas de Sensibilidad Microbiana , Pirimidinas/farmacología , Pirimidinas/uso terapéutico , Factores de Riesgo , Factores Socioeconómicos , Sudáfrica/epidemiología , Resultado del Tratamiento , Triazoles/farmacología , Triazoles/uso terapéutico , VoriconazolRESUMEN
STUDY OBJECTIVE: To analyze the impact of a comprehensive care bundle directed by an antimicrobial stewardship team (AST) on the management of candidemia. DESIGN: Single-center, quasi-experimental study. SETTING: A 930-bed academic hospital. PATIENTS: Seventy-eight patients with candidemia were evaluated; 41 patients received the candidemia care bundle (AST group), and 37 did not (historical control group). MEASUREMENTS AND MAIN RESULTS: A candidemia care bundle was developed by an interdisciplinary AST, incorporating key elements from the Infectious Diseases Society of America's Clinical Practice Guidelines for the Management of Candidemia. The AST made prospective recommendations in accordance with the care bundle. Bundle elements were utilization of appropriate antifungal agents with appropriate duration of use, removal of intravenous catheters, repeat blood cultures, monitoring of time until clearance of candidemia, and performance of ophthalmologic examinations. Compliance with all candidemia care bundle elements was significantly higher in the AST group versus the control group (78.0% vs 40.5%, p=0.0016). Implementation of the care bundle significantly improved rates of ophthalmologic examination (97.6% vs 75.7%, p=0.0108), selection of appropriate antifungal therapy (100% vs 86.5%, p=0.0488), and compliance with an appropriate duration of therapy (97.6% vs 67.7%, p=0.0012). In addition, the AST group had fewer excess total days of therapy beyond the recommended duration than the control group (5 vs 83 total antifungal days). Length of hospitalization (20 vs 21 days, p=0.9184), time until clearance of candidemia (3 vs 3 days p=0.610), rate of persistent candidemia (22% vs 40.5%, p=0.126), and rate of recurrent candidemia (4.9% vs 5.4%, p=0.916) were similar in the AST group versus the control group. CONCLUSION: A comprehensive candidemia care bundle directed by our institution's AST improved the management of patients with candidemia. We encourage further exploration into the use of care bundles by ASTs as part of their multifaceted approach to promoting appropriate antimicrobial utilization and optimizing the management of patients with infectious diseases.